An early case report of two advanced-stage prostate cancer patients showed complete remission after [225Ac]Ac-PSMA-617 PRRT with no relevant treatment adverse effects, overall supporting that [225Ac]Ac-PSMA-617 could represent a new salvage therapy in advanced PCa [53]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.